Blood test for early liver disease detection targets bile acids

What happened: a new blood test for early liver disease detection

Researchers at The University of Toledo reported a blood test approach for early liver disease detection that focuses on bile acids, which they say are often missing from routine clinical blood panels.

In the report, the team argues that elevated bile acids can be among the earliest biological signs that liver function may be impaired, even before symptoms or conventional blood markers show clear problems.

• Routine panels commonly measure cholesterol, bilirubin, and triglycerides, but not bile acids, according to the researchers.
• They describe early elevation of bile acids in blood as silent and asymptomatic, which can delay detection until later markers “catch up.”

What the evidence shows in this blood test for early liver disease detection

The work, published in the American Journal of Physiology—Gastrointestinal and Liver Physiology (2026), reports that red blood cells exposed to elevated bile acids become more resistant to rupturing under osmotic stress, and that this can be detected with a simple test.

The researchers first observed the pattern in multiple genetic mouse models of spontaneous cholemia, and they report seeing the same pattern in people with cholestatic liver disease treated at the University of Toledo Medical Center.

• Human sample: blood from 23 patients with cholestatic liver disease compared with 23 age- and gender-matched individuals without signs of liver disease.
• Proposed mechanism: elevated bile acid exposure shifts red blood cell membrane lipids—more cholesterol and less of the major phospholipid—making the membrane more rigid and resistant to osmotic stress.
• Timeline/handling described: during a blood glucose test, an added four microliters of blood could be collected and tested, with an answer in 10–20 minutes, according to the researchers.

Why bile acids matter for early liver disease detection

Bile acids are compounds made by the liver that help with digestion and absorption of fat-soluble vitamins, and under normal conditions they circulate between the liver and intestine and remain out of the bloodstream.

The researchers explain that if liver function is impaired or bile flow to the gallbladder is blocked, bile can spill over and build up in the blood, a condition they call cholemia, which may appear before conventional markers like bilirubin and liver injury enzymes.

• Symptoms can come late: the report notes that fatigue, abdominal discomfort, and jaundice may appear after liver disease has moved beyond its earliest and most treatable stages.
• Clinical gap highlighted: because routine bloodwork doesn’t measure bile acids, early cholemia may go undetected until later-stage markers register changes.

Practical context for metabolic health: what to ask about

For people tracking metabolic health, the practical point from this study is that a routine-looking panel may not include bile acids, even though the researchers view bile acids as an early signal of impaired liver function.

The team’s proposed workflow is a fast add-on style screen that looks for high bile acids indirectly through red blood cell behavior, which they say could help identify people who need follow-up evaluation sooner.

• If you’re discussing lab work with a clinician, you can ask whether bile acids are assessed and, if not, whether there is a reason to check them in your case.
• The paper also points to pregnant women as a group that may need careful monitoring and could benefit from earlier detection approaches, according to the researchers.

Limitations and what this test does not prove yet

This report describes a screening method that distinguished cholestatic liver disease patients with elevated bile acids from matched individuals without signs of liver disease, but it does not establish how the test performs across all causes of liver disease or in broad population screening.

The paper’s findings combine mouse model results and a small, single-center comparison in people, so larger and more diverse clinical studies would be needed to confirm accuracy, clinical cutoffs, and how the test should be used alongside standard liver markers.

• The human data described involve 23 patients with cholestatic liver disease and 23 matched controls, which limits how widely the results can be generalized.
• The approach is presented as a way to detect elevated bile acids (an early warning sign), not as a stand-alone diagnosis of a specific liver disease cause.